同步放化疗治疗非小细胞肺癌的临床分析.docVIP

同步放化疗治疗非小细胞肺癌的临床分析 　　 　　 　　 　　[摘要] 目的 探讨同步放化疗治疗非小细胞肺癌（NSCLC）的临床效果及毒副反应。 方法 选择本院2011年1月~2013年1月收治入院的采用同步放化疗治疗的Ⅲ期NSCLC患者100例为观察组，另选择本院同期采用序贯放化疗治疗的Ⅲ期NSCLC患者100例为对照组，分析两组患者的治疗效果与毒副反应情况。 结果 观察组中总有效55例，有效率为55.0%，对照组中总有效35例，有效率为35.0%，两组比较，差异有统计学意义（P0.05）。 结论 同步放化疗治疗Ⅲ期NSCLC的疗效优于序贯放化疗，不良反应增大但可耐受，值得进一步研究。 　　[关键词] 非小细胞肺癌；放射疗法；化学疗法；同步放化疗；序贯放化疗 　　[中图分类号] R734.2[文献标识码] A[文章编号] 1674-4721（2014）05（a）-0023-03 　　 　　Clinical analysis of concurrent chemoradiation therapy treating non-small cell lung cancer 　　LI Zhen-bin CHEN Xuan TANG Xiao-mei YI Xiang-jun 　　Department of Oncology,Jiangxi Chest Hospital,Nanchang 330006,China 　　[Abstract] Objective To investigate the clinical effect and toxicity of concurrent chemoradiation therapy treating non-small cell lung cancer (NSCLC). Methods 100 patients with NSCLC on stage Ⅲ from January 2011 to January 2013 given concurrent chemoradiation therapy were selected as the observation group,and another 100 cases given sequential chemoradiotherapy treatment at the same time were included in the control group.The treatment effect and toxicity of the two groups were compared. Results 55 cases in the observation group were effective,the total effective rate was 55.0%,35 cases in the control group were effective,the total effective rate was 35.0%,and there was a statistical difference between the two groups (P0.05). Conclusion Concurrent chemoradiation is superior to sequential chemoradiotherapy for treating NSCLC on stage Ⅲ,the adverse reactions increases but tolerable.It is worthy of further study. 　　[Key words] Non-small-cell lung cancer;Radiation therapy;Chemotherapy;Concurrent chemoradiotherapy;Sequential chemoradiotherapy 　　近几年的临床证明对非小细胞肺癌（non-small-cell lung cancer，NSCLC）特别是局部晚期的NSCLC单一的治疗手段效果不满意，多学科的综合治疗是改善患者预后的手段之一[1]。目前常用的方法有两种：化疗与放疗序贯进行、化疗与放疗同期进行[2]。本文重点介绍非小细胞肺癌的内科治疗，探讨同步放化疗疗法治疗NSCLC的临床效果及毒副反应。 　　1 资料与方法 　　1.1 一般资料 　　选择本院2007年1月~2009年1月收治入院的采用同步放化疗疗法治疗的Ⅲ期NSCLC患者200例作为观察对象。所有患者均经组织病理学或细胞学证实诊断为Ⅲ期NSCLC（WHO1997 年分期标准）病例[3]，纳入标准